From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)- one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1689-1696

  De Corte, Bart L ^a,b  

^a Drug Discovery   (United States)

^b Johnson Johnson Pharmaceutical R D ^*

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7, TETRAHYDRO 5 METHYLIMIDAZO[4,5,1 JK](1,4) BENZODIAZEPIN 2(1H) ONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ALPHA ANILINOPHENYLACETAMIDE; BENZODIAZEPINE DERIVATIVE; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; DIARYLPYRIMIDINE; DIARYLTRIAZINE; EFAVIRENZ; EMIVIRINE; ETRAVIRINE; IMIDOYL THIOUREA; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; R100943; R14458; R15345; R82913; R93514; R95845; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIVIRAPINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZODIAZEPINES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1 REVERSE TRANSCRIPTASE; IMIDAZOLES; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 15444380338     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040127p     Document Type: Review

References (59)

1. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
2. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220.
3. Mitsuya, H. Progress in antiviral therapy in AIDS: dideoxynucleosides and azidothymidine. Med. Immunol. 1987, 14, 297-305.
4. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St. Clair, M. H.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
5. Mitsuya, H.; Broder, S. Strategies for antiviral therapy in AIDS. Nature 1987, 325, 773-778.
6. Gallo, R. C.; Montagnier, L. AIDS in 1988. Sci. Am. 1988, 259, 41-48.
7. Gallo, R. C.; Montagnier, L. The chronology of AIDS research. Nature 1987, 326, 435-436.
8. Yarchoan, R.; Mitsuya, H.; Broder, S. AIDS therapies. Sci. Am. 1988, 259, 110-119.
9. Yarchoan, R.; Berg, G.; Brouwers, P.; Fischl, M. A.; Spitzer, A. R.; Wichman, A.; Grafman, J.; Thomas, R. V.; Safai, B.; Brunetti, A. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987, 1 (8525), 132-135.
10. Yarchoan, R.; Klecker, R. W.; Weinhold, K. J.; Markham, P. D.; Lyerly, H. K.; Durack, D. T.; Gelmann, E.; Lehrman, S. N.; Blum, R. M.; Barry, D. W. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986, 1 (8481), 575-580.
11. Sharma, P. L.; Nurpeisov, V.; Hernandez-Santiago, B.; Beltran, T.; Schinazi, R. F. Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Curr. Top. Med. Chem. 2004, 4, 895-921.
12. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
13. Kukla, M. J.; Breslin, H. J.; Diamond, C. J.; Grous, P. P.; Ho, C. Y.; Miranda, M.; Rodgers, J. D.; Sherrill, R. G.; De Clercq, E.; Pauwels, R.; Andries, K.; Moens, L. J.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4] benzodiazepin-2(1H)-one (TIBO) derivatives. 2. J. Med. Chem. 1991, 34, 3187-3197.
14. Kukla, M. J.; Breslin, H. J.; Pauwels, R.; Fedde, C. L.; Miranda, M.; Scott, M. K.; Sherrill, R. G.; Raeymaekers, A.; Van Gelder, J.; Andries, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H) -one (TIBO) derivatives. J. Med. Chem. 1991, 34, 746-751.
15. White, E. L.; Buckheit, R. W., Jr.; Ross, L. J.; Germany, J. M.; Andries, K.; Pauwels, R.; Janssen, P. A. J.; Shannon, W. M.; Chirigos, M. A. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991, 16, 257-266.
16. Pauwels, R.; Andries, K.; Debyser, Z.; Kukla, M. J.; Schols, D.; Breslin, H. J.; Woestenborghs, R.; Desmyter, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 1994, 38, 2863-2870.
17. Breslin, H. J.; Kukla, M. J.; Ludovici, D. W.; Mohrbacher, R.; Ho, W.; Miranda, M.; Rodgers, J. D.; Hitchens, T. K.; Leo, G.; Gauthier, D. A.; Ho, C. Y.; Scott, M. K.; De Clercq, E.; Pauwels, R.; Andries, K.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5- methylimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) Derivatives. 3. J. Med. Chem. 1995, 38, 771-793.
18. Ho, W.; Kukla, M. J.; Breslin, H. J.; Ludovici, D. W.; Grous, P. P.; Diamond, C. J.; Miranda, M.; Rodgers, J. D.; Ho, C. Y.; De Clercq, E.; Pauwels, R.; Andries, K.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk)][1,4]benzodiazepin- 2(1H)-one (TIBO) Derivatives. 4. J. Med. Chem. 1995, 38, 794-802.
19. Breslin, H. J.; Kukla, M. J.; Kromis, T.; Cullis, H.; De Knaep, F.; Pauwels, R.; Andries, K.; De Clercq, E.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4] benzodiazepin-2(1H)-ones (TIBO) analogues. Bioorg. Med. Chem. 1999, 7, 2427-2436.
20. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
21. Hajos, G.; Riedl, Z.; Molnar, J.; Szabo, D. Nonnucleoside reverse transcriptase inhibitors. Drugs Future 2002, 25, 47-62.
22. Balzarini, J. Current Status of Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1. Curr. Top. Med. Chem. 2004, 4, 921-944.
23. Szczech, G. M.; Furman, P.; Painter, G. R.; Barry, D. W.; Borroto-Esoda, K.; Grizzle, T. B.; Blum, M. R.; Sommadossi, J.; Endoh, R.; Niwa, T.; Yamamoto, M.; Moxham, C. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, 123-130.
24. Balzarini, J.; Naesens, L.; Verbeken, E.; Laga, M.; Van Damme, L.; Parniak, M.; Van Mellaert, L.; Anne, J.; De Clercq, E. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998, 12, 1129-1138.
25. Borkow, G.; Barnard, J.; Nguyen, T. M.; Belmonte, A.; Wainberg, M. A.; Parniak, M. A. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 1997, 71, 3023-3030.
26. Ruiz, N.; Nusrat, R.; Lauenroth-Mai, E.; Berger, D.; Walworth, C.; Bacheler, L. T.; Ploughman, L.; Tsang, P.; Labriola, D.; Echols, R.; Levy, R. DPC 083-203 Study Team. Study DPC 083-201: A phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. Presented at the 9th Conference of Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002; Abstract No. 6.
27. Ruiz, N.; Nusrat, R.; Lazzarin, A.; Arasteh, K.; Goebel, F.-D.; Audagnotto, S.; Rachlis, A.; Arribas, J.; Ploughman, L.; Fiske, W.; Labriola, D.; Levy, R.; Echols, R. DPC 083-203 Study Team. Study DPC-083-203: A phase II double-blind (DB) comparison of 3 once-daily doses of NNRTI DPC 083 vs 600 mg efavirenz (EFV) in combination with 2 NRTIs in HIV antiretroviral (ARV) treatment naive patients. Presented at the 9th Conference of Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002; Abstract No. 7.
28. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
29. Sorbera, L. A.; Castaner, J.; Bayes, M. Capravirine. Drugs Future 2003, 28, 1149-1158.
30. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
31. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
32. Arnold, E.; Das, K.; Ding, J.; Yadav, P. N. S.; Hsiou, Y.; Boyer, P. L.; Hughes, S. H. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des. Discovery 1996, 13, 29-47.
33. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A. J.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
34. Nanni, R. G.; Ding, J.; Jacobo-Molina, A.; Hughes, S. H.; Arnold, E. Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug Discovery Des. 1993, 1, 129-150.
35. Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
36. Pauwels, R.; de Bethune, M.-P.; Andries, K.; Stoffels, P.; Janssen, P.; De Clercq, E. Discovery, development and characterization of agents active against the AIDS virus. J. Recept. Signal Transduction Res. 1995, 15, 609-616.
37. Pauwels, R.; Andries, K.; Debyser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A. M.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
38. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D., Jr.; Jessen, S.; Lu, X.; Ysiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H., Jr.; Kroeger Smith, M. B.; Koepke, M.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
39. Romero, D. L.; Morge, R. A.; Genin, M. J.; Biles, C.; Busso, M.; Resnick, L.; Althaus, I. W.; Reusser, F.; Thomas, R. C.; Tarpley, W. G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1- methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 1993, 36, 1505-1508.
40. Dueweke, T. J.; Poppe, S. M.; Romero, D. L.; Swaney, S. M.; So, A. G.; Downey, K. M.; Althaus, I. W.; Reusser, F.; Busso, M.; Resnick, L. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 1993, 37, 1127-1131.
41. Freimuth, W. W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv. Exp. Med. Biol. 1996, 394, 279-289.
42. Nottet, H. S.; Oteman, M. H.; Visser, M. R.; Verhoef, J. Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother. 1994, 33, 366-368.
43. Ludovici, D. W.; Kukla, M. J.; Grous, P. G.; Krishnan, S.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; De Clercq, E.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
44. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
45. Deeks, S. G. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquired Immune Defic. Syndr. 1999, 26 (Suppl. 1), S25-S33.
46. Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Miles, P. D.; Parsons, M. E.; Prain, H. D.; White, G. R. Cyanoguanidinethiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine. J. Med. Chem. 1977, 20, 901-906.
47. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; Moereels, H. E. L.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
48. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
49. Di Fabio, S.; Van Roey, J.; Giannini, G.; van den Mooter, G.; Spada, M.; Binelli, A.; Pirillo, M. F.; Germinario, E.; Belardelli, F.; de Bethune, M.-P.; Vella, S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003, 17, 1597-1604.
50. van Herrewege, Y.; Vanham, G.; Michiels, J.; Fransen, K.; Kestens, L.; Andries, K.; Janssen, P.; Lewi, P. A series of diaryltriazines and diarylpyrimidines are highly potent non-nucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 2004, 48, 3684-3689.
51. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.; De Corte, B.; Vingerhoets, J.; Pauwels, R.; de Bethune, M.-P. TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 4680-4686.
52. Udier-Blagovic, M.; Tirado-Rives, J.; Jorgensen, W. L. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J. Am. Chem. Soc. 2003, 125, 6016-6017.
53. Lewi, P. J.; De Jonge, M.; Daeyaert, F.; Koyman, L.; Vinkers, M.; Heeres, J.; Janssen, P. A. J.; Arnold, E.; Das, K.; Clark, A. D.; Hughes, S. H.; Boyer, P. L.; De Bethune, M. P.; Pauwels, R.; Andries, K.; Kukla, M.; Ludovici, D.; De Corte, B.; Kavash, R.; Ho, C. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J. Comput.-Aided Mol. Des. 2003, 17, 398.
54. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231.
55. Gruzdev, B.; Rakhmanova, A.; Doubovskaya, E.; Yakovlev, A.; Peeters, M.; Rinehart, A.; de Dier, K.; Baede-Van Dijk, P.; Parys, W.; van't Klooster, G. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17, 2487-2494.
56. Gazzard, B. G.; Pozniak, A. L.; Rosenbaum, W.; Yeni, G. P.; Staszewski, S.; Arasteh, K.; De Dier, K.; Peeters, M.; Woodfall, B.; Stebbing, J.; van't Klooster, G. A. An open-label assessment of TMC 125, a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17, 49-54.
57. Two recent publications discuss the pharmacological profile and clinical potential of etravirine in detail: (a) Pauwels, R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 2004, 4, 437-446. (b) Haslinger, B. A.; Arendt, G. TMC-125 (Tibotec). Curr. Opin. Invest. Drugs 2004, 5, 208-213.
58. Two recent publications discuss the pharmacological profile and clinical potential of etravirine in detail: (a) Pauwels, R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 2004, 4, 437-446. (b) Haslinger, B. A.; Arendt, G. TMC-125 (Tibotec). Curr. Opin. Invest. Drugs 2004, 5, 208-213.
59. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Béthune, M.-P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Volovik Frenkel, Y.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino] benzonitrile (R278474, Rilpivirine). J. Med. Chem. 2005, 48, xxx-xxx.